MedPath

Catherine Bollard

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

14

Active:4
Completed:7

Trial Phases

2 Phases

Phase 1:13
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials

Phase 1
13 (92.9%)
Phase 2
1 (7.1%)

HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

Phase 2
Recruiting
Conditions
HIV Associated Lymphoma
Interventions
Biological: Bone Marrow Transplant
First Posted Date
2021-07-23
Last Posted Date
2023-12-28
Lead Sponsor
Catherine Bollard
Target Recruit Count
12
Registration Number
NCT04975698
Locations
🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

Georgetown, Washington, District of Columbia, United States

🇺🇸

H. Lee Moffitt Cancer Center, Tampa, Florida, United States

and more 8 locations

Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)

Phase 1
Active, not recruiting
Conditions
HIV-Infected Individuals
Interventions
First Posted Date
2020-01-30
Last Posted Date
2025-04-29
Lead Sponsor
Catherine Bollard
Target Recruit Count
8
Registration Number
NCT04248192
Locations
🇺🇸

Johns Hopkins University(Jhu), Baltimore, Maryland, United States

Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)

Phase 1
Active, not recruiting
Conditions
Congenital Heart Disease (CHD)
Interventions
First Posted Date
2020-01-22
Last Posted Date
2025-04-29
Lead Sponsor
Catherine Bollard
Target Recruit Count
17
Registration Number
NCT04236479
Locations
🇺🇸

Children's National Health System, Washington, District of Columbia, United States

Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

Phase 1
Active, not recruiting
Conditions
Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma
Interventions
Biological: TAA-T cells
First Posted Date
2019-02-18
Last Posted Date
2025-07-03
Lead Sponsor
Catherine Bollard
Target Recruit Count
18
Registration Number
NCT03843294
Locations
🇺🇸

Utah University School of Medicine/Huntsman Cancer Institute, Salt Lake City, Utah, United States

Multi-antigen T Cell Infusion Against Neuro-oncologic Disease

Phase 1
Active, not recruiting
Conditions
Brain Tumor
Interventions
First Posted Date
2018-08-29
Last Posted Date
2025-04-29
Lead Sponsor
Catherine Bollard
Target Recruit Count
33
Registration Number
NCT03652545
Locations
🇺🇸

Brain Tumor Institute, Children's National Medical Center, Washington, District of Columbia, United States

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath